These increases happen at four-week intervals, but the timeline can be extended if needed
doi:10.1038/s41591-024-02970-5 PubMed: This substudy demonstrated that retatrutide reduced liver fat by 81-82% at the 8mg and 12mg doses over 24 weeks, providing evidence of retatrutides multi-system metabolic benefits beyond weight loss
What Is Half-Life
Clinical Evidence: In participants with T2DM, Retatrutide 12 mg reduced HbA1c by 2.02% at 48 weeks, compared to 0.5% with placebo
In September 2022, Eli Lilly published the results of its preclinical studies on LY3437943 in the journal Cell Metabolism, in an article titled "LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept." In vitro and in vivo validation of the triple agonist effect of LY3437943: Eli Lilly's research results show that LY3437943 demonstrates superior weight loss effects compared to GLP-1 receptor (GLP-1R) selective agonists (GLP-1 RA), GLP-1R and GCGR dual agonists (Cotadutide or 05677), and GLP-1R and GIPR dual agonists